144 related articles for article (PubMed ID: 33303217)
1. Uncovering the role of apolipoprotein C-III in insulin resistance.
Aguilar-Recarte D; Palomer X; Vázquez-Carrera M
Clin Investig Arterioscler; 2021; 33(2):108-115. PubMed ID: 33303217
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
[TBL] [Abstract][Full Text] [Related]
3. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
Chan DC; Nguyen MN; Watts GF; Barrett PH
J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
[TBL] [Abstract][Full Text] [Related]
4. Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.
Liu YZ; Cheng X; Zhang T; Lee S; Yamauchi J; Xiao X; Gittes G; Qu S; Jiang CL; Dong HH
J Biol Chem; 2016 Jul; 291(28):14695-705. PubMed ID: 27226540
[TBL] [Abstract][Full Text] [Related]
5. HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: A Multicenter Cohort Study.
Yamamoto R; Jensen MK; Aroner S; Furtado JD; Rosner B; Hu FB; Balkau B; Natali A; Ferrannini E; Baldi S; Sacks FM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2928-e2940. PubMed ID: 33839794
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
Zheng C; Khoo C; Furtado J; Sacks FM
Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
8. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
10. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB; Averna M
Curr Atheroscler Rep; 2023 Mar; 25(3):67-76. PubMed ID: 36689070
[TBL] [Abstract][Full Text] [Related]
11. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.
Chen M; Breslow JL; Li W; Leff T
J Lipid Res; 1994 Nov; 35(11):1918-24. PubMed ID: 7868970
[TBL] [Abstract][Full Text] [Related]
13. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.
Cohn JS; Patterson BW; Uffelman KD; Davignon J; Steiner G
J Clin Endocrinol Metab; 2004 Aug; 89(8):3949-55. PubMed ID: 15292332
[TBL] [Abstract][Full Text] [Related]
14. Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.
Adiels M; Taskinen MR; Björnson E; Andersson L; Matikainen N; Söderlund S; Kahri J; Hakkarainen A; Lundbom N; Sihlbom C; Thorsell A; Zhou H; Pietiläinen KH; Packard C; Borén J
Diabetes Obes Metab; 2019 Aug; 21(8):1861-1870. PubMed ID: 30972934
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic insulin expression on lipid metabolism in diabetic mice.
Qu S; Zhang T; Dong HH
J Diabetes; 2016 May; 8(3):314-23. PubMed ID: 25851734
[TBL] [Abstract][Full Text] [Related]
16. Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects.
Maraninchi M; Padilla N; Béliard S; Berthet B; Nogueira JP; Dupont-Roussel J; Mancini J; Bégu-Le Corroller A; Dubois N; Grangeot R; Mattei C; Monclar M; Calabrese A; Guérin C; Desmarchelier C; Nicolay A; Xiao C; Borel P; Lewis GF; Valéro R
J Clin Lipidol; 2017; 11(2):495-506.e3. PubMed ID: 28502507
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia.
Moberly JB; Attman PO; Samuelsson O; Johansson AC; Knight-Gibson C; Alaupovic P
Miner Electrolyte Metab; 1999; 25(4-6):258-62. PubMed ID: 10681649
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Norata GD; Tsimikas S; Pirillo A; Catapano AL
Trends Pharmacol Sci; 2015 Oct; 36(10):675-687. PubMed ID: 26435212
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.
Åvall K; Ali Y; Leibiger IB; Leibiger B; Moede T; Paschen M; Dicker A; Daré E; Köhler M; Ilegems E; Abdulreda MH; Graham M; Crooke RM; Tay VS; Refai E; Nilsson SK; Jacob S; Selander L; Berggren PO; Juntti-Berggren L
Proc Natl Acad Sci U S A; 2015 May; 112(20):E2611-9. PubMed ID: 25941406
[TBL] [Abstract][Full Text] [Related]
20. Targeting FoxO1 for hypertriglyceridemia.
Kim DH; Zhang T; Ringquist S; Dong HH
Curr Drug Targets; 2011 Aug; 12(9):1245-55. PubMed ID: 21443465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
